submit to the journals

ASCO Highlights

flipper_slider

Editor's Choice

Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular...

ASCO Highlights Videos

touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical...
Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may...
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs...
touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this...
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What is...
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines. 1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11) 2. What...
Editorial board member, Eleni Andreopoulou, discusses interventions to improve the quality of life of patients with breast cancer throughout their treatment. Q. What personalized interventions improve the quality of life of breast cancer patients during and after chemotherapy treatment? (0:...
Editorial board member, Eleni Andreopoulou, from Weill Cornell Medical College in New York, US, discusses molecular subtyping and advances in molecularly-targeted therapy in triple-negative breast cancer. Q1. What are the major challenges of treating triple-negative breast cancer? (0:11) Q2...
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma. 1. What is the latest progress on the clinical development of...
Martin Edelman from the Fox Chase Cancer Center in Philadelphia, PA, US discusses current treatments and unmet needs in small cell lung cancer and how research into immunotherapy, including dinutuximab and irinotecan as a second-line therapy, can contribute to treatment strategies. 1. What...
Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment. 1. How are personalised strategies impacting the treatment...
Editorial board member Ulka Vaishampayan from the Karmanos Cancer Center, Wayne State University, Detroit, MI, US, talks to us about the place of personalized therapy in patients with advance renal cancer and the potential role of X4P-001 in treatment paradigms in the near future. 1. What are...
Jennifer C King, PhD, Director of Science and Research at the Lung Cancer Alliance, Washington, DC, talks to us about unmet needs in non-small cell lung cancer and the role Lung Cancer Alliance plays in supporting patients and research. 1. Could you tell us a little about the services...
Part 2 of 2 - Dr Ajjai Alva explains checkpoint inhibitors and discusses their use in combination with IL-2 for patients who do not respond to checkpoint inhibitors alone. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017